Healthcare services company Chemed Corporation (NYSE: CHE) will be announcing earnings results this Thursday after market close. Here’s what investors should know.
Chemed missed analysts’ revenue expectations last quarter, reporting revenues of $639.3 million, flat year on year. It was a disappointing quarter for the company, with a significant miss of analysts’ full-year EPS guidance estimates and a significant miss of analysts’ revenue estimates.
Is Chemed a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Chemed’s revenue to be flat year on year, slowing from the 9.8% increase it recorded in the same quarter last year.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Chemed has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at Chemed’s peers in the healthcare providers & services segment, some have already reported their Q1 results, giving us a hint as to what we can expect. UnitedHealth delivered year-on-year revenue growth of 2%, beating analysts’ expectations by 1.7%, and Quest reported revenues up 9.2%, topping estimates by 2.7%.
Read our full analysis of UnitedHealth’s results here and Quest’s results here.
There has been positive sentiment among investors in the healthcare providers & services segment, with share prices up 7.5% on average over the last month. Chemed is up 1.2% during the same time and is heading into earnings with an average analyst price target of $443 (compared to the current share price of $377.91).
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
